Successful treatment of acute antibody-mediated rejection of liver allograft with imlifidase: A case report

Abstract

Although the incidence of acute antibody mediated rejection in liver transplantation is low, the consequences of acute antibody mediated rejection can be devastating, often leading to severe fibrotic changes and early graft loss. Conventional treatment modalities for management of moderate-to-severe acute antibody mediated rejection in liver transplant continue to rely on of corticosteroids, plasmapheresis, and intravenous immunoglobulin. However, management of refractory, severe antibody mediated rejection remains without a clear gold-standard approach. This case report describes successful first use of Imlifidase, an Ig-G degrading enzyme, for management of acute refractory antibody mediated rejection following orthotopic liver transplant. This 41-year-old woman developed acute antibody meditated rejection and donor specific antibodies within two weeks of undergoing an A2 to O liver transplant. Following unsuccessful treatment with conventional modalities, treatment with Imlifidase resulted in normalization of liver function, resolution of antibody mediated rejection on surveillance biopsy, and disappearance of donor specific antibodies. Imlifidase could represent a promising treatment for refractory antibody mediated rejection in liver transplantation and warrants further study.